By Nancy Lapid (Reuters) -Exposure to wildfire smoke may increase lung cancer patients' risk of dying from their disease, ...

Today, cancer stage and tumor size tell which patients will receive adjuvant chemotherapy. But the rise of biomarker testing ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

CHICAGO -- Biomarker-driven adjuvant therapy for intermediate/high-risk non-small cell lung cancer (NSCLC) led to ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

For the second time in as many months, the lack of statistically significant overall survival data sent shares of Summit Therapeutics Inc. sliding, despite otherwise positive findings for PD-1/VEGF ...

A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain ...